Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 675-683

  Poynard, Thierry ^a   Moussalli, Joseph ^a   Munteanu, Mona ^b   Thabut, Dominique ^a   Lebray, Pascal ^a   Rudler, Marika ^a   Ngo, Yen ^b   Thibault, Vincent ^a   Mkada, Helmi ^c   Charlotte, Frederic ^a   Bismut, Françoise Imbert ^c   Deckmyn, Olivier ^b   Benhamou, Yves ^a   Valantin, Marc Antoine ^a   Ratziu, Vlad ^a   Katlama, Christine ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Biopredictive   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cirrhosis; Elastography; FibroTest FibroSure

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ATAZANAVIR; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; NEVIRAPINE;

ADULT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; BILE DUCT CARCINOMA; BODY MASS; ELASTOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

CIRRHOSIS; ELASTOGRAPHY; FIBROSURE; FIBROTEST™;

ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84884418448     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.015     Document Type: Article

References (37)

1. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832 (Pubitemid 27129209)
2. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
3. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 MMWR Recomm Rep 61 2012 1 32
4. N. Hirashima, M. Mizokami, and E. Orito Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha J Gastroenterol Hepatol 11 1996 955 958 (Pubitemid 26338284)
5. T. Mashitani, H. Yoshiji, and M. Yamazaki Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report Cases J 2 2009 18
6. E.L. Ellis, and D.A. Mann Clinical evidence for the regression of liver fibrosis J Hepatol 56 2012 1171 1180
7. T. Poynard, Y. Ngo, and M. Munteanu Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies Antivir Ther 15 2010 617 631
8. T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313 (Pubitemid 34465173)
9. S.L. George, B.R. Bacon, E.M. Brunt, K.L. Mihindukulasuriya, J. Hoffmann, and A.M. Di Bisceglie Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients Hepatology 49 2009 729 738
10. R. D'Ambrosio, A. Aghemo, and M.G. Rumi A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis Hepatology 56 2012 532 543
11. La Haute Autorité de Santé (HAS) in France - The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. http://www.has-sante.fr/portail/display.jsp?id=c-476486 (Accessed August 2007).
12. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
13. T. Poynard, M. Munteanu, and O. Deckmyn Validation of liver fibrosis biomarker (FibroTest™) for assessing liver fibrosis progression: proof of concept and first application in a large population J Hepatol 57 2012 541 548
14. T. Poynard, J. McHutchison, M. Manns, R.P. Myers, and J. Albrecht Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin Hepatology 38 2003 481 492 (Pubitemid 36919870)
15. Y. Ngo, M. Munteanu, and D. Messous A prospective analysis of the prognostic value of biomarkers (FibroTest™) in patients with chronic hepatitis C Clin Chem 52 2006 1887 1896 (Pubitemid 44470696)
16. J. Vergniol, J. Foucher, and E. Terrebonne Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C Gastroenterology 2011 1979 1970 1979
17. S. Liu, M. Schwarzinger, F. Carrat, and J.D. Goldhaber-Fiebert Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients PLoS One 6 2011 e26783
18. F. Imbert-Bismut, V. Ratziu, and L. Pieroni Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 2001 1069 1075 (Pubitemid 32322537)
19. Y. Benhamou, M. Bochet, and V. Di Martino Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Hepatology 30 1999 1054 1058 (Pubitemid 29458296)
20. T. Poynard, M. Munteanu, and F. Imbert-Bismut Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C Clin Chem 50 2004 1344 1355 (Pubitemid 38970641)
21. T. Poynard, M.F. Yuen, V. Ratziu, and C.L. Lai Viral hepatitis C Lancet 362 2003 2095 2100 (Pubitemid 38035201)
22. T. Poynard, M. Munteanu, and O. Deckmyn Applicability and precautions of use of liver injury biomarker FibroTest™. A reappraisal at 7 years of age BMC Gastroenterol 11 2011 39
23. L. Castéra, J. Foucher, and P.H. Bernard Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations Hepatology 51 2010 828 835
24. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293 (Pubitemid 26260021)
25. T. Poynard, G. Lenaour, and J.C. Vaillant Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis Clin Gastroenterol Hepatol 10 2012 e7
26. T. Poynard, V. Ratziu, F. Charlotte, Z. Goodman, J. McHutchison, and J. Albrecht Rates and risk factors of liver fibrosis progression in persons with chronic hepatitis C J Hepatol 34 2001 730 739 (Pubitemid 32488789)
27. J. Hintze NCSS 8 2012 NCSS, LLC Kaysville, Utah, USA www.ncss.com
28. H.A. Innes, S.J. Hutchinson, and S. Allen Hepatitis C Clinical Database Monitoring Committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care Hepatology 5 2011 1547 1558
29. A.J. van der Meer, B.J. Veldt, and J.J. Feld Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
30. T. Tsumura, S. Takaki, and H. Aikata Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after clearance of HCV-RNA by interferon treatment Nihon Shokakibyo Gakkai Zasshi 106 2009 674 683
31. H.B. El-Serag, E.A. Engels, and O. Landgren Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans Hepatology 49 2009 116 123
32. J.H. Tabibian, C. Landaverde, J. Winn, S.A. Geller, and N.N. Nissen Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis Ann Hepatol 8 2009 64 67
33. K. Patel, M. Friedrich-Rust, and Y. Lurie FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus World J Gastroenterol 17 2011 4581 4589
34. P. Halfon, F. Carrat, and P. Bédossa Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02 Antivir Ther 14 2009 211 219
35. T. Poynard, V. De Ledinghen, and J.P. Zarski Relative performances of FibroTest™, FibroScan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard J Hepatol 56 2012 541 548
36. T.R. Morgan, M.G. Ghany, and H.Y. Kim Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
37. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 57 2012 1110 1125